Free Trial

Grace Therapeutics (GRCE) Competitors

$3.88 +0.16 (+4.30%)
As of 02:49 PM Eastern

GRCE vs. VTYX, NBTX, CLYM, MCRB, SAVA, SGMT, TSVT, LPTX, RENB, and IGMS

Should you be buying Grace Therapeutics stock or one of its competitors? The main competitors of Grace Therapeutics include Ventyx Biosciences (VTYX), Nanobiotix (NBTX), Climb Bio (CLYM), Seres Therapeutics (MCRB), Cassava Sciences (SAVA), Sagimet Biosciences (SGMT), 2seventy bio (TSVT), Leap Therapeutics (LPTX), Renovaro (RENB), and IGM Biosciences (IGMS). These companies are all part of the "pharmaceutical preparations" industry.

Grace Therapeutics vs.

Ventyx Biosciences (NASDAQ:VTYX) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, community ranking, valuation, profitability, dividends, media sentiment, risk and earnings.

Ventyx Biosciences has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500. Comparatively, Grace Therapeutics has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500.

Ventyx Biosciences received 31 more outperform votes than Grace Therapeutics when rated by MarketBeat users.

CompanyUnderperformOutperform
Ventyx BiosciencesOutperform Votes
31
46.97%
Underperform Votes
35
53.03%
Grace TherapeuticsN/AN/A

Grace Therapeutics is trading at a lower price-to-earnings ratio than Ventyx Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ventyx BiosciencesN/AN/A-$192.96M-$2.36-0.91
Grace TherapeuticsN/AN/A-$12.85M-$1.01-3.84

97.9% of Ventyx Biosciences shares are owned by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are owned by institutional investors. 18.2% of Ventyx Biosciences shares are owned by company insiders. Comparatively, 13.5% of Grace Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Grace Therapeutics' return on equity of -18.09% beat Ventyx Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Ventyx BiosciencesN/A -54.94% -50.01%
Grace Therapeutics N/A -18.09%-15.38%

Ventyx Biosciences presently has a consensus target price of $10.00, suggesting a potential upside of 366.20%. Given Ventyx Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Ventyx Biosciences is more favorable than Grace Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ventyx Biosciences
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Grace Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Ventyx Biosciences had 12 more articles in the media than Grace Therapeutics. MarketBeat recorded 12 mentions for Ventyx Biosciences and 0 mentions for Grace Therapeutics. Ventyx Biosciences' average media sentiment score of 0.80 beat Grace Therapeutics' score of 0.00 indicating that Ventyx Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Ventyx Biosciences Positive
Grace Therapeutics Neutral

Summary

Ventyx Biosciences beats Grace Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Grace Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GRCE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GRCE vs. The Competition

MetricGrace TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$39.34M$6.56B$5.41B$9.25B
Dividend YieldN/A2.96%5.37%3.99%
P/E Ratio-3.849.8988.9917.55
Price / SalesN/A337.821,229.4079.77
Price / CashN/A64.1243.6036.96
Price / Book0.595.115.024.73
Net Income-$12.85M$154.90M$117.89M$224.61M
7 Day Performance13.12%1.79%2.12%1.76%
1 Month Performance1.57%1.93%4.08%5.37%
1 Year PerformanceN/A5.10%26.88%21.70%

Grace Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GRCE
Grace Therapeutics
N/A$3.88
+4.3%
N/AN/A$39.34MN/A-3.84N/A
VTYX
Ventyx Biosciences
2.9497 of 5 stars
$1.96
+1.0%
$10.00
+410.2%
+5.6%$138.59MN/A-0.8330
NBTX
Nanobiotix
2.9159 of 5 stars
$2.92
+1.7%
$12.00
+311.0%
-56.4%$137.63M$36.22M0.00100News Coverage
CLYM
Climb Bio
3.5651 of 5 stars
$2.00
+7.0%
$10.00
+400.0%
N/A$134.45MN/A-0.94N/AGap Up
MCRB
Seres Therapeutics
3.5919 of 5 stars
$0.78
+1.8%
$5.08
+551.7%
-40.6%$133.18M$126.33M-3.39330
SAVA
Cassava Sciences
4.44 of 5 stars
$2.71
+3.8%
$111.50
+4,014.4%
-90.1%$130.38MN/A-1.9630
SGMT
Sagimet Biosciences
1.309 of 5 stars
$4.17
+0.2%
$23.00
+451.6%
-39.4%$127.92M$2M0.008
TSVT
2seventy bio
2.3999 of 5 stars
$2.42
+1.3%
$9.00
+271.9%
-20.7%$124.84M$45.62M-1.30440News Coverage
LPTX
Leap Therapeutics
2.0907 of 5 stars
$3.25
+5.2%
$7.50
+130.8%
-22.9%$124.53M$1.50M-1.6840
RENB
Renovaro
1.0818 of 5 stars
$0.78
-4.4%
N/A-85.0%$123.80MN/A-0.8120Positive News
IGMS
IGM Biosciences
4.7084 of 5 stars
$2.00
+17.0%
$5.50
+175.0%
-83.7%$118.93M$2.92M-0.55190High Trading Volume

Related Companies and Tools


This page (NASDAQ:GRCE) was last updated on 1/22/2025 by MarketBeat.com Staff
From Our Partners